Edit

Sinovation Ventures

http://www.sinovationventures.com
Last activity: 26.08.2026
Active
Portfolio
1
Mentions
52
Investment Type: Venture Capital

Portfolio 1

DateNameWebsiteTotal RaisedLocation
03.04.2026Syneron Bi...syneronbio.com$150MChina

Mentions in press and media 52

DateTitleDescription
26.08.2026China's BCI Race Accelerates: Gestala Raises US$84 Million in Six MonthsSHANGHAI and CHENGDU, China, Aug. 26, 2026 /PRNewswire/ -- Gestala officially launched on January 1, 2026. Six months later, the company had completed two financing rounds totaling RMB 570 million, or approximately US$84 million. The financ...
09.07.2026Surging users, widening losses, and leased compute: Behind SiliconFlow’s IPO filingOn the final day of the second quarter, SiliconFlow filed a listing application with the Hong Kong Stock Exchange. The IPO was submitted under Chapter 18C as a pre-commercial company. Huatai International and Haitong International are the j...
15.06.2026China remains indispensable, but reality check awaits AI boom, says Sinovation’s Richard Yang-
08.04.2026Xiaokuo files for Hong Kong IPO as it expands beyond oral careShenzhen-registered Xiaokuo Technology formally filed its prospectus with the Hong Kong Stock Exchange on March 27, 2026, seeking a main board listing. CMB International is serving as a joint sponsor. Founded in 2015, Xiaokuo is focused on ...
04.04.2026Syneron Bio Fuels Innovation with $150M InvestmentSyneron Bio secured $150 million in Series B financing. This major investment drives its intelligent Synova platform. The capital fuels advanced macrocyclic peptide drug discovery. It targets critical unmet needs across oncology, autoimmune...
03.04.2026Syneron Bio Closes $150M Series B FinancingSyneron Bio, a Beijing, China-based intelligent platform-driven macrocyclic peptide drug discovery company, closed a $150m Series B financing round. The round was led by an international life-science fund, with co-lead participation from De...
03.04.2026Syneron Bio: $150 Million Raised For Macrocyclic Peptide Drug Discovery Platform And Pipeline AdvancementSyneron Bio announced the completion of a $150 million Series B financing round, strengthening its position as a developer of intelligent platform-driven macrocyclic peptide therapeutics and accelerating its push toward clinical development...
03.04.2026Syneron Bio Announces Completion of $150 Million Series B FinancingBEIJING, April 3, 2026 /PRNewswire/ -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international ...
29.01.2026China's AI Reshapes Global Tech Landscape: Open-Source Dominance and Price WarsChina's AI industry is rapidly expanding its global footprint. It champions open-source models and aggressive pricing strategies. This approach drives substantial market share growth worldwide. Beijing's "AI Plus" initiative integ...
23.01.2026China spurs Africa's leap in AI technologyAt a converted warehouse on the outskirts of Nairobi, Kenya, a dozen young programmers gather around used laptops to develop an application. The artificial intelligence model they are using is trained to spot crop disease from a single smar...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In